School of Pharmacy, University of Queensland, 20 Cornwall Street, Woolloongabba, Brisbane, QLD, 4102, Australia.
Department of Nephrology, Princess Alexandra Hospital, Brisbane, QLD, Australia.
Eur J Drug Metab Pharmacokinet. 2024 Nov;49(6):751-761. doi: 10.1007/s13318-024-00914-3. Epub 2024 Aug 29.
The pharmacokinetics of immunosuppressant drugs may change with advancing age, potentially affecting patient outcomes.
To characterise the effects of age on the pharmacokinetic and exposure parameters of tacrolimus, mycophenolate, and prednisolone.
Pharmacokinetic profiling, involving whole blood tacrolimus, total and free plasma mycophenolic acid (MPA), total plasma mycophenolic acid glucuronide (MPAG), and total and free plasma prednisolone, was performed in an older and younger adult cohort. Thirteen samples were drawn on a single occasion, pre-oral dose and then at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 9, and 12 h post-dose. Non-compartmental analysis was conducted using the PKNCA package, and pharmacokinetic and exposure parameters were compared between age groups using a Mann-Whitney test. A regression analysis was conducted for free MPA and MPAG using significant variables of interest.
This exploratory study included 21 older and 18 younger adults. Dose-adjusted tacrolimus, total MPA and free prednisolone pharmacokinetic parameters were not different between age groups; however, for free MPA and MPAG, older recipients had significantly greater minimum and maximum concentrations, trough concentrations, and half-life. There was a two-fold increase in free MPA exposure in older adults (median dose-adjusted AUC: 1284 vs. 684 μg h/L, p < 0.0001); MPAG exposure similarly increased. Age was significantly associated with free MPA and MPAG exposure, and free MPA exposure was associated with haematocrit (p < 0.05).
Differences in MPA were found with advancing age and may be due to altered kidney function, haematocrit, plasma protein binding and/or drug absorption. Future research should explore specific covariate contributions to this further.
免疫抑制剂药物的药代动力学可能会随着年龄的增长而发生变化,从而可能影响患者的预后。
描述年龄对他克莫司、霉酚酸和泼尼松龙的药代动力学和暴露参数的影响。
在老年和年轻成年队列中进行了药代动力学分析,包括全血他克莫司、总血浆和游离型霉酚酸(MPA)、总血浆霉酚酸葡萄糖醛酸(MPAG)以及总血浆和游离型泼尼松龙。在单次给药前和给药后 0.25、0.5、0.75、1、1.25、1.5、2、3、4、6、9 和 12 小时采集 13 个样本。使用 PKNCA 包进行非房室分析,并使用 Mann-Whitney 检验比较年龄组之间的药代动力学和暴露参数。使用有意义的变量进行回归分析,以评估游离型 MPA 和 MPAG。
本探索性研究纳入了 21 名老年患者和 18 名年轻患者。年龄组之间,经过剂量调整的他克莫司、总 MPA 和游离型泼尼松龙的药代动力学参数没有差异;然而,对于游离型 MPA 和 MPAG,老年患者的最小和最大浓度、谷浓度和半衰期均显著更高。老年患者的游离型 MPA 暴露量增加了两倍(中位数剂量调整后的 AUC:1284 比 684μg·h/L,p<0.0001);MPAG 暴露量也相应增加。年龄与游离型 MPA 和 MPAG 暴露量显著相关,游离型 MPA 暴露量与红细胞压积相关(p<0.05)。
随着年龄的增长,MPA 存在差异,这可能是由于肾功能、红细胞压积、血浆蛋白结合和/或药物吸收的改变所致。未来的研究应进一步探讨特定协变量对这一差异的贡献。